Tag: Sanofi

Sanofi and Google To Establish New Virtual Innovation Lab

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of emerging data...

Sanofi Appointed New CEO

At its meeting on June 6th of 2019, Sanofi’s Board of Directors unanimously appointed Paul Hudson as Chief Executive Officer of the Group, to succeed Olivier Brandicourt who has decided to retire. ...

Sanofi Diabetes Treatment Phase 3 Results Showed Significant Reduction in Blood Sugar Levels

In a Phase 3 study1 evaluating adults with type 2 diabetes inadequately controlled by GLP-1 receptor agonist (GLP-1 RA) treatments, Soliqua® /Suliqua®2 (insulin glargine 100 Units/mL and lixisenatide)...

Sanofi vs Amgen Litigations over Praluent Patents in Germany

Germany’s highest civil court on Tuesday rejected French drugmaker Sanofi’s bid to fend off a legal challenge by U.S. rival Amgen against Sanofi’s cholesterol drug Praluent. In the latest setback f...

Sanofi Enters into Strategic Partnership with Enable Injections

Enable Injections, Inc., a company developing and manufacturing advanced wearable infusion devices for combination products, announced it has entered into a multi-product development agreement with Sa...

Nanolek to Complete Sanofi Vaccine Localization by 2022

nanolek
Nanolek plans to launch the full-cycle production of a 5-in-1 infant vaccine under a technology transfer project with Sanofi Pasteur (France) by 2022. The first phase in the project to localize the...

Cegedim Announced Innovative Collaboration with Sanofi

sanofi
Cegedim has announced that it is set to engage in an innovative collaboration on Real World Data for healthcare improvement in Europe with Sanofi. The company has announced that it will provide San...

Regeneron and Sanofi to Publish Updated Libtayo Data

cancer treatment
Regeneron Pharmaceuticals, Inc. and Sanofi announced that positive updated data for Libtayo® (cemiplimab-rwlc) in locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC) will be share...

Sanofi Dupixent Gained EU Approval

Sanofi and Regeneron’s Dupixent will now enter the asthma market in Europe, the new expansion confirming its blockbuster profile. The dual IL-4 and IL-13 inhibitor has just gained approval for the ...

EC Approved Dupixent for Severe Asthma

The European Commission has approved Dupixent® (dupilumab) for use in adults and adolescents 12 years and older as an addon maintenance treatment for severe asthma with type 2 inflammation characteriz...

Sanofi Pasteur Received FDA Approval for Dengvaxia

sanofi-pasteur
The U.S. Food and Drug Administration announced today the approval of Dengvaxia, the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in...

Sanofi Q1 Earnings Rose 11%

Sanofi’s profit rose more than expected last quarter, powered by sales of vaccines and newcomer Dupixent, an eczema and asthma drug set to become a blockbuster. The stock had its biggest gain so far t...

EU Granted Marketing Authorization for Sanofi and Lexicon’s Zynquista

sanofi
The European Commission has granted marketing authorization for Zynquista™ (sotagliflozin), developed by Sanofi and Lexicon. Zynquista is now approved in the European Union, at once-daily doses of 200...

Sanofi and Alnylam Agreed to Conclude and Option Phase of 2014 RNAi Therapeutics Collaboration

Sanofi and Alnylam have agreed to conclude the research and option phase of the companies' 2014 RNAi therapeutics alliance in rare genetic diseases. The material collaboration terms for patisiran, vut...

Sanofi Plans Fly Supply of Flu Vaccine to UK after Brexit

Drugs company Sanofi has plans to fly supplies of flu vaccine into the UK if other transport routes are disrupted after the country leaves the EU. Hugo Fry, the managing director of its UK arm, tol...

FDA Does not Approve Sanofi and Lexicon Application for Zynquista

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for investigational Zynquista™ (sotagliflozin), a dual SGLT1 and SGLT2 inhibitor ...